Chronic Obstructive Pulmonary Diseases:Journal of the COPD Foundation

Volume 13, Issue 6 - 2026 | Plain Language Summaries

Short summaries, in non-technical, simple language of articles published in the most recent issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation are provided here. Links to the full, published research article are provided with each summary. The Journal is indexed by PubMed, PubMed Central, Scopus and Web of Science.

All summaries for the current issue are listed below in the order of publication, scroll down.

A Phase IIb Randomized Trial of Belimumab to Reduce Atherogenic Autoantibodies in COPD Patients

R. Chad Wade, MD; Sarah Robison, MD; J. Michael Wells, MD; Takudzwa Mkorombindo, MD; Maida Chaudhry, MD; Mohamed Kheder Aly Awad, MD; Young-il Kim, PhD; Kaiyu Yuan, MD; Mohamed Mohsen Abdalla, BS; Mark T. Dransfield, MD; Steven R. Duncan, MD

People with lung disease from smoking often develop heart disease, which is a leading cause of death in this group. Prior research has shown that this may be linked to the immune system attacking the body in an abnormal way.

In this study, researchers first measured an immune protein, “anti-GRP78 autoantibodies,” in patients' blood and compared it to calcium buildup in their heart arteries that were seen on chest scans. Patients with higher levels of the protein tended to have more calcium buildup, suggesting a real connection between the two. Researchers then tested whether a medicine called belimumab, already used for a different immune disease, could lower this abnormal protein. Sixteen patients received either the medicine or a placebo, an inactive drug, through monthly infusions. Those who received the medicine had lower protein levels by the end of treatment, while the placebo group did not change. Protective antibodies that guard against infection stayed the same, and no serious side effects were clearly caused by the medicine.

These findings suggest this treatment is safe and worth studying further. A larger study is now needed to confirm whether lowering this immune protein actually reduces heart disease in people with lung disease.


Randomized Double-Blinded Pilot Study of Doxycycline for HIV-Associated COPD and Emphysema

Robert J. Kaner, MD; Sarah L. O’Beirne, MD, PhD; Amy Krambrink, MS; Cathie Spino, ScD; He S. Yang, PhD; Yuan-Shan Zhu, MB, PhD; Ronald G. Crystal, MD; Marshall J. Glesby, MD, PhD

Emphysema develops more often in people living with HIV who smoke as compared to people without HIV. There is no approved medication to slow emphysema progression. Other studies have observed increased enzymes that can damage lung tissue in people living with HIV who smoke. Doxycycline, an antibiotic medicine, may be able to block these enzymes.

We conducted a small study to test the safety and tolerability (the ease and comfort of taking) doxycycline in people living with HIV who have emphysema and/or chronic obstructive pulmonary disease (COPD) to determine if a larger trial is needed. We randomly assigned study participants to take doxycycline or a matching placebo pill (an inactive pill containing no actual medicine) for 24 weeks and found that doxycycline was safe and easy to take. We noted significant drug levels in both blood and the lungs. We also saw a decrease in a specific type of inflammatory cell in the lung. These results suggest the need for a larger, longer trial of doxycycline to test if it can slow the progression of emphysema in people living with HIV.


Nurse-Led Pursed-Lip and Abdominal Breathing Training Improves Pulmonary Function and Functional Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease: A Prospective Randomized Controlled Trial

Changfang Geng, RN; Quan Gao, RN; Jia Yu, RN; Wei Huang, RN

Chronic obstructive pulmonary disease (COPD) causes shortness of breath and can make daily activities hard. There is limited information on whether breathing exercises taught by a nurse can help people with this condition who are not in the hospital.

In this study, 218 adults with stable COPD participated. Half of the individuals learned 2 breathing techniques/methods: pursed-lip breathing and abdominal breathing. They practiced for 30 minutes, 3 times a week, for 12 weeks. The other half received usual care without the breathing techniques.

After 12 weeks, the breathing exercise group showed improvement. They could walk farther in 6 minutes and reported fewer symptoms. Their lung function and oxygen levels also improved. The program was safe, and participants completed about 87% of the sessions. These findings suggest that a simple nurse-led breathing program can benefit people with stable COPD. Larger studies in multiple hospitals are now needed to confirm these results.


Multimorbidity and Acute-Care Use Among Older Decedents With Advanced Chronic Obstructive Pulmonary Disease: A Retrospective Population-Based Cohort Study

Anat Romem, RN, NP, DNP; Ayal Romem, MD, MHA

Advanced chronic obstructive pulmonary disease (COPD) often causes severe breathing problems and repeated hospital visits. Many older people with this illness also live with several other serious health conditions, yet little is known about how these combined problems shape care during the last year of life.

We reviewed routinely collected health records for 2,261 people aged 55 years or older who had advanced COPD and died between 2016 and 2023. We did not include individuals who died in 2021 because the pandemic disrupted normal care. We examined their other illnesses, hospital and emergency care, procedures, and whether they received palliative care, which focuses on comfort, symptom relief, and support. Patients had an average of 4 additional health conditions and experienced frequent hospital care during their final year. Only 7.4% had any palliative care. Men had more recorded health conditions and procedures, while women were older when they died.

These findings show that advanced lung disease near the end of life is usually part of a set of larger medical problems. Identifying individuals with repeated hospital use and multiple illnesses may help health systems also identify patients who need earlier supportive and palliative care.


Pharmacodynamic Equivalence and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate With a Next-Generation Propellant Versus Hydrofluoroalkane-134a Propellant: A Randomized Phase 3 Study in Chronic Obstructive Pulmonary Disease

Matthew Camiolo, MD, PhD; Hitesh Pandya, MBChB, MD; Mandeep Jassal, MD; Artur Bednarczyk, MD; Yubo Tan, MSc; Margareta Puu, PhL; David Petullo, MSc; Patrik Bondarov, MSc; Artur Mark-Pawlowicz, MD; Jie Mei, MD, PhD; Lars Pettersson, MSc; Mehul Patel, MBBS, FRCP, PhD; MeiLan K. Han, MD, MS

Budesonide, glycopyrronium, and formoterol (BGF), is a medicine used to treat chronic obstructive pulmonary disease (COPD). This study compares 2 inhalers that deliver BGF. A new inhaler uses a new spray gas or propellant, HFO-1234ze, that helps deliver the medicine. This new gas is better for the environment than HFA-134, which is the gas that the current inhaler uses. The goal of the study was to find out whether the new inhaler worked as well and was as safe as the current inhaler.

The study included 296 people with COPD. Each person used 1 of 3 inhalers in a random order: the new inhaler, the current inhaler, and an inhaler that did not contain medicine (a placebo inhaler), each 2 times a day, for a period of 4 weeks. Researchers measured changes in breathing and recorded side effects.

Both the new and current inhaler improved lung function. And they both improved lung function more than the placebo inhaler, which contained no BGF medicine. Side effects were also similar between the inhalers. These results suggest that the more environmentally friendly inhaler could replace the current inhaler without reducing how well it works or how safe it is. This could benefit both people with COPD and the environment.


Clinician-Perceived Barriers and Facilitators for Initiation and Management of Noninvasive Ventilation Among Patients With Chronic Hypercapnia From COPD: A Qualitative Study

Patricia J. Checinski, MD; Kaitland M. Byrd, PhD; Wassim W. Labaki, MD, MS; Thomas S. Valley, MD, MSc; Philip J. Choi, MD; Elizabeth M. Viglianti, MD, MPH, MSc

At least 25% of individuals with COPD have continual high levels of carbon dioxide, or chronic hypercapnia, which is associated with worse health results. Noninvasive ventilation uses a breathing machine with a mask that pushes oxygen into the nose and mouth, making it easier to breathe with less effort and less work from the chest muscles. Using noninvasive ventilation at home can improve survival and lower the risk of being readmitted to a hospital. Many professional medical societies recommend noninvasive ventilation for patients with chronic hypercapnia from COPD, yet many doctors still do not use it with their COPD patients.

To better understand why this is true, we interviewed 15 pulmonologists across the United States. We asked them about how they manage chronic hypercapnia in patients with COPD and any barriers they experience in caring for these individuals. We found reasons at the patient level (e.g., not following their treatment as prescribed), the physician level (e.g., difficulty getting the necessary testing), and the practice or clinic level (e.g., not enough staff support; challenges with insurance approval) that kept patients from receiving noninvasive ventilation as a treatment option. Consistent screening guidelines, a step-by-step plan for treatment, a simpler process for getting insurance approved, improved physician education, and better support and access to testing could help general pulmonologists care for these patients.


Nighttime Symptom Burden in Chronic Obstructive Pulmonary Disease: A Qualitative Study

Sarah Miller, PhD, RN; Hayley D. Germack, PhD, RN; Meredith Bell, PharmD; Norbert Feigler, MD; Randy Legg, PharmD, MBA; Kathleen Henderson; Chip Kreisman, BSB; Karen Winkler, MSc; Dorsa Khazaei, MSc; Tommi Tervonen, PhD; Gerard J. Criner, MD

Many people living with chronic obstructive pulmonary disease (COPD) struggle with symptoms during the night, including shortness of breath, coughing, and mucus buildup. These symptoms can interrupt sleep and leave people feeling tired and less able to carry out everyday activities. Despite this, nighttime symptoms are not often discussed in detail.

To better understand this issue, we interviewed 30 adults in the United States who were receiving treatment for COPD but continued to experience symptoms. Participants described their nighttime symptoms, how those symptoms affected their sleep and daily lives, and how they manage them.

Many participants said they woke up frequently during the night because of breathing problems, coughing, or mucus. Poor sleep often led to tiredness, difficulty concentrating, anxiety, reduced physical activity, and fewer social activities during the day. People reported using a variety of strategies to cope, including maintaining sleep routines, relaxation techniques, medications, rescue inhalers, and other supportive approaches.

These results suggest that nighttime symptoms remain an important challenge for many people with COPD, even when they are receiving treatment. Asking about nighttime symptoms during routine medical visits may help health care providers better understand patients' needs and support symptom management throughout the day and night.


Comparison of Nebulized Long-Acting Muscarinic Antagonist Revefenacin to Ipratropium in COPD Patients With Acute Respiratory Failure Requiring Mechanical Ventilation: Results of the RARICO Study

Igor Barjaktarevic, MD, PhD; Matthew Dartt, MBA, BSRT, RRT-ACCS; Siyan Chen, MS; D’Mitri Champion, RRT; Roberto Mempin, MD; Yongyus Dejsatha, RRT; Joseph Van Vleet, BSRC, RRT; Steven V. Chang, MD, PhD; Oscar Estrada, MD; Timothy Young, MD; Russell G. Buhr, MD, PhD; Donald Tashkin, MD; Joanne M. Bando, MD

Revefenacin is a type of medicine for COPD that is used in a nebulizer (a machine that turns liquid medicine into a mist that is breathed in through a mask or mouthpiece). It is usually used with patients who have stable COPD. However, little has been reported on its use in hospitalized COPD patients and especially those in critical care settings with acute respiratory failure.

In our study, we compared revefenacin and ipratropium (another COPD medicine), each delivered via a vibrating mesh nebulizer in individuals with COPD and acute respiratory failure who were intubated and mechanically ventilated (they had a breathing tube in their airways that was attached to a ventilator which helped them breathe). Of 21 enrolled individuals, 12 received revefenacin once daily, followed by 3 treatments of a placebo (an inactive treatment) every 6 hours. Nine individuals received ipratropium in 4 daily doses.

There was no significant difference in any major health results between the 2 drugs, except the revefenacin treatments made it easier for air to move in and out of the lungs. We found that using the revefenacin medicine may spare nearly 20 minutes of respiratory therapist time on a daily basis. Our study shows that revefenacin may be a promising option for treating patients hospitalized with COPD.


Using Electronic Health Records to Identify Participants for a Multicenter COPD Clinical Trial

Priya A. Prasad, PhD, MPH; Stephanie L. LaBedz, MD; Janet Holbrook, PhD; Richard A. Mularski, MD, MSHS, MCR; Stephen I. Rennard, MD; Elizabeth Sugar, PhD; Robert A. Wise, MD; Nina E. Bracken, APRN; Andrew Auerbach, MD, MPH; Jerry A. Krishnan, MD, PhD; for the RELIANCE study team

Clinical trials depend on finding people who meet specific study requirements, but identifying eligible participants by manually reviewing medical records can be slow and take a lot of effort. This study examined whether electronic health records could be used to more efficiently identify people who might qualify for a large clinical trial that compared 2 treatments for chronic obstructive pulmonary disease (COPD), the RELIANCE trial.

We conducted a study at 33 U.S. clinical sites that were part of the RELIANCE trial and used electronic health record information to identify adults 40 years of age or older with COPD. We then reviewed a random sample of 990 hospital and outpatient records to determine whether the information needed to decide if patients were eligible to be in the RELIANCE study could be found in the electronic health record.

We found that approximately 36% of hospitalized patients appeared eligible for the RELIANCE study based on reviewing hospital charts. However, more than one-quarter of the records lacked information needed to fully determine if the patients were eligible. These findings suggest that taking information from the electronic health record can make study recruitment more efficient, particularly when reviewing hospitalized patients, but better methods are needed to address missing information in the medical records.


Statins as Regulatory T Cell Modulators in COPD Early Disease

Won-Dong Kim, MD; Don D. Sin, MD

Smokers with COPD are known to have a reduced number of the cells that control the lungs’ immune reaction, and smokers without COPD have higher numbers of these cells. Thus, immune regulatory cells—which help control the body's immune response to disease and allergens—are suspected to prevent the development of COPD.

Granzyme B is considered a possible marker for or indicator of immune regulatory cells. Granzyme B is an enzyme that is released to fight viruses and cancer but can also cause inflammation. In lung tissue from individuals with COPD, the number of cells with granzyme B were lower in individuals with severe COPD, and higher in individuals with mild COPD. An animal study showed that statins (a drug currently used to lower cholesterol and help lower the risk of heart attacks) increase the number of immune regulatory cells and the amount of granzyme B secreted. Animal studies have also shown that statins taken 3 months after smoking are not effective. However, starting statins when smoking was first started slowed down the progression of COPD and lessened its severity. These findings suggest that statins may have the potential to prevent the development of COPD when started in the early stages of COPD, but more studies are needed to determine whether statins can prevent or slow the progression of COPD.